Cargando…

Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy

SIMPLE SUMMARY: The human immune system has several mechanisms to attack and eliminate lymphomas. However, the MYC oncogene is thought to facilitate escape from this anti-tumor immune response. Since patients with MYC overexpressing lymphomas face a significant dismal prognosis after treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Jonge, A. Vera, Mutis, Tuna, Roemer, Margaretha G. M., Scheijen, Blanca, Chamuleau, Martine E. D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589056/ https://www.ncbi.nlm.nih.gov/pubmed/33092116 http://dx.doi.org/10.3390/cancers12103052

Ejemplares similares

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
por: van der Horst, Hilma J., et al.
Publicado: (2021)

Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma
por: Eertink, Jakoba J., et al.
Publicado: (2022)

Immunotherapies in Non-Hodgkin’s Lymphoma
por: Bezombes, Christine, et al.
Publicado: (2021)

Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma
por: Renner, Christoph, et al.
Publicado: (2018)

Immunotherapy in indolent Non-Hodgkin's Lymphoma
por: Amhaz, Ghid, et al.
Publicado: (2022)

Epigenetics, c-Myc and Aggressive B-cell Lymphomas
por: Zhang, Yizhuo, et al.
Publicado: (2012)

Novel Approaches in Molecular Characterization of Classical Hodgkin Lymphoma
por: van Bladel, Diede A. G., et al.
Publicado: (2022)

The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
por: Mendeville, Matias, et al.
Publicado: (2022)

Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
por: Holthof, Lisa C., et al.
Publicado: (2020)

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020)

Increased frequency of the S allele of the L-myc oncogene in non-Hodgkin's lymphoma.
por: Crossen, P. E., et al.
Publicado: (1994)

Constitutive overexpression of a novel 21 kDa protein by Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphomas
por: Zhou, Minglong, et al.
Publicado: (2008)

Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
por: Pytlik, Robert, et al.
Publicado: (2020)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2019)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
por: Zhao, Pengcheng, et al.
Publicado: (2023)

Rasburicase-Induced Methemoglobinemia in a Patient with Aggressive Non-Hodgkin’s Lymphoma
por: Alessa, Mohammed A., et al.
Publicado: (2015)

Extranodal large B-cell type aggressive non-Hodgkin's lymphoma
por: Batra, Ranmeet, et al.
Publicado: (2014)

Aggressive squamous cell carcinoma as a harbinger of non-Hodgkin lymphoma
por: Callaghan, Daniel J., et al.
Publicado: (2018)

The Role of NOTCH1, GATA3, and c-MYC in T Cell Non-Hodgkin Lymphomas
por: Al-Khreisat, Mutaz Jamal, et al.
Publicado: (2022)

MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas
por: Aquino, Gabriella, et al.
Publicado: (2013)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
por: Hallam, Simon
Publicado: (2018)

Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
por: Nakhoda, Shazia, et al.
Publicado: (2022)

Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma
por: Kang, Ka-Won, et al.
Publicado: (2018)

A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma
por: Schuhmacher, Bianca, et al.
Publicado: (2016)

Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment
por: Drees, Esther E. E., et al.
Publicado: (2022)

High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?
por: Pophali, Priyanka A., et al.
Publicado: (2020)

The effects of MYC on tumor immunity and immunotherapy
por: Li, Jiajin, et al.
Publicado: (2023)

Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma
por: Evens, Andrew M., et al.
Publicado: (2022)

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
por: Randall, Michael P., et al.
Publicado: (2023)

Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?
por: Hackshaw, A, et al.
Publicado: (2004)

Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas.
por: Johnson, P. W., et al.
Publicado: (1993)

Impact of complete surgical resection on outcome in aggressive non‐Hodgkin lymphoma treated with immunochemotherapy
por: Schmitz, Christine, et al.
Publicado: (2020)

Prognostic Impact of Baseline Immunologic Profile in Aggressive B-cell non-Hodgkin’s Lymphomas
por: Ramadan, Safaa, et al.
Publicado: (2021)

The Benefit of Telemonitoring in the Prevention of Septic Shock in a Patient with Aggressive Non-Hodgkin’s Lymphoma
por: Dudová, Lucie, et al.
Publicado: (2023)

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
por: Lynch, Ryan C., et al.
Publicado: (2022)

Aggressive B-Cell Lymphomas
por: Naresh, Kikkeri N., et al.
Publicado: (2012)

The Role of the MYC/miR-150/MYB/ZDHHC11 Network in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
por: Ziel-Swier, Lotteke J. Y. M., et al.
Publicado: (2022)

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B(5b )(CYB5B)
por: Murphy, Derek, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_c6kb3cojfj9fju8mnbjhpiq77v